Judson I, et al. - Among participants recruited from 12 hospitals in the UK (n=7), Spain (n=3), and Australia (n=2), researchers intended to distinguish the impact of cediranib (a tyrosine-kinase inhibitor) from the inherently indolent nature of alveolar soft-part sarcoma (ASPS), given that a substantial activity has been reported in non-randomised studies for cediranib in ASPS. For inclusion, participants were required to have received no anti-cancer therapy within 4 weeks prior to trial entry, with exception of palliative radiotherapy. Findings revealed a significant clinical activity with cediranib in ASPS, a condition that carries a high incidence of metastatic disease and poor long-term prognosis, and for which conventional chemotherapy is not efficacious.